All News
-
UB-311 Vaccine Safe, Effective in Mild Alzheimer’s Patients, Phase 2a Trial Suggests
United Neuroscience’s Alzheimer’s vaccine candidate UB-311 was found safe and well-tolerated, triggering an antibody response against beta-amyloid in most of the patients, according to Phase 2a trial results.UB-311 Vaccine Safe, Effective in Mild Alzheimer’s Patients, Phase 2a Trial Suggestsmore -
Dr. Siegel: Alzheimer’s disease — Why results from a vaccine and a test offer concrete reasons for hope
Today there are new reasons to be hopeful about the fight against Alzheimer’s disease. There is a new Alzheimer’s vaccine known as UB 311, produced by a small company, United Neuroscience, in Dublin, Ireland, that has just delivered promising results in phase two clinical trials in humans.Dr. Siegel: Alzheimer’s disease — Why results from a vaccine and a test offer concrete reasons for hopemore -
United Neuroscience To Move Forward Alzheimer’s Vaccine After Promising Phase IIa
Private, Dublin-based biotech United Neuroscience says it plans to rapidly advance its active Alzheimer's vaccine immunotherapy UB-311 after reporting positive top-line results from a Phase IIa study of 42 patients on Jan. 16.United Neuroscience To Move Forward Alzheimer’s Vaccine After Promising Phase IIamore
